Biomarkers /
JAK3
Overview
Janus kinase 3 (JAK3) is a gene that encodes a protein-tyrosine kinase that functions in receptor-mediated signal transduction and is highly expressed in immune cells. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
JAK3 is altered in 1.90% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, high grade ovarian serous adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in JAK3 are JAK3 Mutation (1.55%), JAK3 Amplification (0.23%), JAK3 Fusion (0.03%), JAK3 Loss (0.05%), and JAK3 A573V (0.05%) [3].
Clinical Trials
Significance of JAK3 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.